ClinicalTrials.gg
CompletedNCT01400698Updated Sep 18, 2013Results posted

Saizen in Intra-uterine Growth Retardation

A Phase 3 interventional study of Saizen® A and Saizen® B in Children Born With Serious Intra-uterine Growth Retardation, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Per ClinicalTrials.gov, last updated 2013-09-18.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Sex
All
01

Study summary

Study of safety of Saizen® in children born with serious intra-uterine growth retardation (IUGR) treated to final height. An open, phase III study involving 17 centers in France.

The study enrolled children who have completed 3 or 2 years of treatment and at least one year of post treatment observation in the Sponsor Studies GF 4001 (Safety and Efficacy of Saizen in the Treatment of Young Children Born with Severe IUGR) or GF 6283 (Effect of Intermittent versus Continuous Saizen Therapy in Young Children Born with Severe IUGR), respectively.

Detailed description: Serious IUGR is a syndrome characterized by low birth length and weight for gestational age (less than 10 percentile). The secretion of growth hormone in response to provocative stimuli (e.g. arginine, insulin) is normal in these children. Apart from low birth weight, children born with IUGR may have minor or major malformations.

A catch-up period with a supraphysiological growth velocity generally occurs during the first 6 to 24 months of life in 80 to 90 percent (%) of these children. This generally allows them to reach normal height. That means that conversely, approximately 10 to 20% of children do maintain a statural handicap. Puberty occurs at a normal age and the retardation in bone maturation present during the first years of life disappears very quickly. This leads to short adult stature in subjects who have not shown spontaneous catch-up during the first years of life. A safe and effective means of promoting growth without accelerating the timing or tempo of puberty would therefore be desirable.

02

Conditions studied

  • Children Born With Serious Intra-uterine Growth Retardation

Keywords

  • Intra-uterine growth retardation (IUGR)
  • Saizen
  • Recombinant human growth hormone (r-hGH)
  • Final height
  • Bone age
  • SGA (Small for Gestational Age)
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous inclusion, good compliance and normal completion of GF4001 or GF6283 in the treatment of growth failure in children born with serious IUGR (3-year continuous r-hGH treatment in GF4001 or 2-year continuous or intermittent r-hGH treatment in GF6283).
  • Increase in height greater than 0.5 standard deviation (SD) during the first 2 years of r-hGH treatment in GF4001 or after 2 years of continuous or intermittent r-hGH treatment in GF6283.
  • A written at the beginning of the pre-study visit must be obtained from the parent(s)/legal guardian(s), with the understanding that consent may be withdrawn by the subject or parents at any time without prejudice to their future medical care. Children able to understand the trial should personally sign and date the written informed consent, too.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Known multiple malformation syndrome with severe psychomotor retardation and/or body hemihypertrophy.
  • Severe psychomotor retardation.
  • Severe congenital malformations.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Saizen® (Continuous or intermittent treatment)

    Drug: Saizen® A

  • Experimental
    Saizen® (Observed and then continuous or no treatment)

    Drug: Saizen® B

  • Other
    Observation only

    Other: Observation only

Interventions

  • Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).

    Also known as: r-hGH, Somatropin

  • Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.

    Also known as: r-hGH, Somatropin

  • OtherObservation only

    Subjects were only observed.

06

What researchers measure

Primary outcomes

  1. Final Height

    Final height was defined as the height reached 1 year after height velocity (HV) was less than 2 centimeter/year (cm/year). Height velocity was the change in height since the previous year's measurement. Height was measured with a wall-mounted stadiometer (or in supine position if the participant's age was less than 3 years) and the measurement was repeated thrice by the same observer. The mean of the values obtained in the repeated measurements was taken for the analysis.

    Time frame: One year after final height was attained up to 10.6 years

  2. Height Standard Deviation Score (HSDS)

    HSDS was calculated as height minus reference mean height divided by SD of the reference mean height, both given by the reference growth table (Sempe) for the corresponding chronological age at the height measurement. Greater HSDS indicate greater height. (Sempe M et al., 1979)

    Time frame: One year after final height was attained up to 10.6 years

Secondary outcomes

  1. Parental Adjusted Height Standard Deviation Score (PAHSDS)

    PAHSDS is the distance between the participant's current and target heights, expressed in units of SD of the height distribution of the reference population. Target height is a measure of the height which the participant could hypothetically reach based only on his parents' heights. Target height standard deviation score (THSDS) was calculated as target height minus mean adult height of the reference population divided by SD of the mean adult height of the reference population.

    Time frame: One year after final height was attained up to 10.6 years

07

Results

Posted Sep 25, 2012

Participant flow

Participants who completed 3 or 2 years treatment and at least 1 year post treatment observation in Sponsor Studies GF 4001 (Safety and Efficacy of Saizen in the Treatment of Young Children Born with Severe IUGR) or GF 6283 (Effect of Intermittent versus Continuous Saizen Therapy in Young Children Born with Severe IUGR), respectively were enrolled.

Participant flow — Overall Study
MilestoneSaizen® Continuous (A1)Saizen® Intermittent (A2)Observed, Not Randomized (B0)Observed Then Randomized to Saizen® (B1)Observed Then Randomized to Observation (B2)Observation (C)
Started23232141415
Completed8120679
Not completed15112876
Withdrew: Lost to follow-up252143
Withdrew: Withdrawal by subject820413
Withdrew: Protocol violation010010
Withdrew: Non-compliance010100
Withdrew: Adverse event100000
Withdrew: Other420210

Outcome measures

PrimaryFinal Height

Final height was defined as the height reached 1 year after height velocity (HV) was less than 2 centimeter/year (cm/year). Height velocity was the change in height since the previous year's measurement. Height was measured with a wall-mounted stadiometer (or in supine position if the participant's age was less than 3 years) and the measurement was repeated thrice by the same observer. The mean of the values obtained in the repeated measurements was taken for the analysis.

Time frame:
One year after final height was attained up to 10.6 years
Reported as:
Mean · cm
Final Height
cmNon-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: Treated
Final Height145.90 ± 16.08150.06 ± 12.89153.27 ± 8.71155.59 ± 8.38
PrimaryHeight Standard Deviation Score (HSDS)

HSDS was calculated as height minus reference mean height divided by SD of the reference mean height, both given by the reference growth table (Sempe) for the corresponding chronological age at the height measurement. Greater HSDS indicate greater height. (Sempe M et al., 1979)

Time frame:
One year after final height was attained up to 10.6 years
Reported as:
Mean · standard deviation score
Height Standard Deviation Score (HSDS)
standard deviation scoreNon-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: Treated
Height Standard Deviation Score (HSDS)-1.45 ± 0.76-1.90 ± 1.73-2.33 ± 1.01-1.99 ± 0.88
SecondaryParental Adjusted Height Standard Deviation Score (PAHSDS)

PAHSDS is the distance between the participant's current and target heights, expressed in units of SD of the height distribution of the reference population. Target height is a measure of the height which the participant could hypothetically reach based only on his parents' heights. Target height standard deviation score (THSDS) was calculated as target height minus mean adult height of the reference population divided by SD of the mean adult height of the reference population.

Time frame:
One year after final height was attained up to 10.6 years
Reported as:
Mean · standard deviation score
Parental Adjusted Height Standard Deviation Score (PAHSDS)
standard deviation scoreNon-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: Treated
Parental Adjusted Height Standard Deviation Score (PAHSDS)-0.82 ± 0.59-1.52 ± 1.92-1.64 ± 1.61-1.24 ± 1.39
Post-hocDuration of Treatment
Time frame:
Up to 10.6 years
Reported as:
Mean · years
Duration of Treatment
yearsNon-Final Height: TreatedFinal Height: Treated
Duration of Treatment4.09 ± 2.924.51 ± 2.20
Post-hocDuration of Participation in the Study
Time frame:
Up to 10.6 years
Reported as:
Mean · years
Duration of Participation in the Study
yearsNon-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: Treated
Duration of Participation in the Study2.08 ± 2.275.29 ± 2.894.10 ± 2.877.02 ± 2.06

Adverse events

Collected over Baseline up to Day 30 after end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Treated—1/32 (3.1%)16/32 (50%)
Treated—13/59 (22%)52/59 (88.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventNot TreatedTreated
EpiphysiolysisMusculoskeletal and connective tissue disorders0/324/59
Knee deformityMusculoskeletal and connective tissue disorders0/322/59
KeratoconusEye disorders1/320/59
Limb asymmetryMusculoskeletal and connective tissue disorders0/321/59
Femur fractureInjury, poisoning and procedural complications0/321/59
Foot fractureInjury, poisoning and procedural complications0/321/59
Head injuryInjury, poisoning and procedural complications0/321/59
Congenital jaw malformationCongenital, familial and genetic disorders0/321/59
Hereditary haemorrhagic telangiectasiaCongenital, familial and genetic disorders0/321/59
AppendicitisInfections and infestations0/321/59
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNot TreatedTreated
HeadacheNervous system disorders1/3210/59
PharyngitisInfections and infestations5/329/59
BronchitisInfections and infestations3/328/59
GastroenteritisInfections and infestations3/327/59
ArthralgiaMusculoskeletal and connective tissue disorders0/327/59
NasopharyngitisInfections and infestations0/326/59
InfluenzaInfections and infestations0/326/59
AcneSkin and subcutaneous tissue disorders1/326/59
Ear infectionInfections and infestations2/324/59
RhinitisInfections and infestations1/324/59

Baseline characteristics

Age Continuous
Age Continuous(years)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Mean10.6 ± 3.09.2 ± 2.412.5 ± 3.19.5 ± 2.610.3 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Female55102141
Male58122550
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Asian20002
Black00011
White813224588
Original Study
Original Study(participants)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
GF400166182252
GF62834742439
Birth Height
Birth Height(cm)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Mean41.8 ± 4.342.2 ± 3.544.8 ± 3.442.3 ± 3.542.8 ± 3.7
Birth Weight
Birth Weight(g)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Mean1848 ± 601.22076.9 ± 520.92312 ± 451.12030.9 ± 573.42085.3 ± 551.8
Length of Gestation
Length of Gestation(weeks)Non-Final Height: Not TreatedNon-Final Height: TreatedFinal Height: Not TreatedFinal Height: TreatedTotal
Mean37 ± 2.937.3 ± 2.638.9 ± 1.537.9 ± 2.837.9 ± 2.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sempé M, Pédron G, Roy-Pernot M-P. Auxologie, méthode et séquences. Paris: Theraplix, 1979.
  • Simon D, Leger J, Fjellestad-Paulsen A, Crabbe R, Czernichow P; SGA Study Group. Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens. Horm Res. 2006;66(3):118-23. doi: 10.1159/000093832. Epub 2006 Jun 12. PubMed 16772718 ↗
  • Fjellestad-Paulsen A, Czernichow P, Brauner R, Bost M, Colle M, Lebouc JY, Lecornu M, Leheup B, Limal JM, Raux MC, Toublanc JE, Rappaport R. Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation. Acta Paediatr. 1998 May;87(5):511-7. doi: 10.1080/08035259850158209. PubMed 9641731 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2011
First posted
Jul 22, 2011
Start
Nov 1998
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Sep 25, 2012
Last update
Sep 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01400698
Collaborators
Merck Serono S.A., Geneva
Responsible party
Sponsor
First posted
Jul 22, 2011
Start date
Nov 1998
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Sep 25, 2012
Last update
Sep 18, 2013

Study contacts

Medical Director
study director · Merck Serono S.A., Geneva
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion